Colorectal cancer (CRC) is one of the leading causes of cancer deaths worldwide ([@pky054-B1]). Disease incidence increases dramatically from age 50 years with approximately 10% of cases occurring earlier ([@pky054-B2]). However, this epidemiologic pattern is shifting, with incidence rising among adults less than age 50 years ([@pky054-B3]). Compared with the older population, young CRC patients tend to present at more advanced stages with poorer outcomes ([@pky054-B4]). Early detection, intervention, and prevention would help to reduce disease incidence and mortality ([@pky054-B4],[@pky054-B5]). Current guidelines for early screening are targeted toward individuals with family history of CRC or carriers of germline pathogenic variants in genes with established CRC risk ([@pky054-B6]).

CRC has a heterogeneous genetic susceptibility profile ([@pky054-B4]). Up to 70% of all CRCs arise sporadically from somatic variants in low- to moderate-penetrance genes. Only 10% are attributed to germline pathogenic variants in CRC predisposition genes including the mismatch repair genes (3%), *APC* (1%), *MUTYH* biallelic (\<1%), and *MUTYH* monoallelic (2%) ([@pky054-B7]). The remaining 20% may be contributed by germline variants in other moderate- to high-penetrance genes not typically associated with CRCs ([@pky054-B8]).

Recent genomic studies on CRC have identified pathogenic germline variants among DNA repair genes not typically associated with CRCs. Pathogenic variants of *BRCA2* and *PALB2* have been consistently seen among CRC patients and a threefold increased risk of developing early-onset CRC has also been reported in *BRCA2* mutation carriers ([@pky054-B7],[@pky054-B11]). However, the mechanism of CRC carcinogenesis has predominantly been overactivation of the Wnt signaling pathway secondary to disruption of tumor suppressors such as APC ([@pky054-B14],[@pky054-B15]). It may be premature to conclude the relevance of DNA repair genes in CRC susceptibility given the limited population and functional evidence ([@pky054-B7],[@pky054-B11],[@pky054-B12]). A study on germline mutations of DNA repair genes among young-onset CRCs identified seven germline pathogenic variants in *BRCA2* and *PALB2* but only one of the tumors showed a loss of heterozygosity (LOH) for *BRCA2* ([@pky054-B12]).

Notably, DNA damage repair processes are not exclusive and often interact on a molecular level ([@pky054-B16]). For instance, the homologous recombination (HR) proteins BRCA1 and BARD1 interact physically with MSH2 and MSH6 to regulate downstream processes in DNA mismatch repair (MMR) ([@pky054-B16]). Therefore, it is possible that defects in HR may contribute to CRC pathogenesis ([@pky054-B17]). Functional studies such as tumor LOH and HR repair analyses, as well as population studies, will be useful in clarifying the relevance of defective HR pathway in CRC development ([@pky054-B7]). We sought to fill this gap by profiling the spectrum of pathogenic variants in DNA repair and CRC predisposition genes and evaluate the functional impact of identified variants within an Asian cohort with young-onset CRC. In addition, to investigate if *PALB2* and *BRCA2* germline variants would indeed result in functional impairment, we evaluated our identified variants functionally.

Materials and Methods
=====================

Study Design
------------

We recruited patients diagnosed with CRC before age 50 years on follow-up status at our general medical oncology center from November 2014 to December 2016. We excluded patients with MMR-deficient tumors given our study aim to investigate CRC predisposition in DNA repair genes beyond the known CRC susceptibility genes. Although some individuals with MMR-deficient tumors may have germline pathogenic variants in these genes, this proportion would be reasonably small given the majority of MMR-deficient tumors were accounted for by somatic or germline MMR gene mutations ([@pky054-B18]). Healthy individuals with no prior history of cancer were obtained from a local database of 831 Asian volunteers (median age = 40 years). Clinicopathological data on age, sex, personal and family (first-degree relatives) cancer history, tumor histology, American Joint Committee on Cancer (AJCC) staging, site, and immunohistochemistry staining for MMR proteins were retrieved from electronic medical records.

Whole-Exome Sequencing
----------------------

Patient-derived genomic DNA was extracted using a QIAamp DNA mini kit (Qiagen, Hilden, Germany) and sequenced on an Illumina Hiseq 4000 (Illumina, Inc, San Diego, CA, USA). Reads were aligned to the human reference genome (hs37d5) as previously described and elaborated in [Supplementary Methods](#sup1){ref-type="supplementary-material"} (available online) ([@pky054-B19]). To prioritize candidate germline variants, we evaluated variants with minor allele frequency (MAF) below 0.01 for functional and genetic evidence of pathogenicity according to American College of Medical Genetics and Genomics (ACMG) criteria and curation tools from ClinGene. MAF was defined in reference to Exome Aggregation Consortium and 1000 Genomes databases and an in-house database of local control population, which provided a better reflection of polymorphisms in the Singaporean population, hence a more accurate estimate of allele frequency for evaluation of PM2 criterion ([@pky054-B20],[@pky054-B21]). MAF of 0.03 was used for genes with autosomal recessive inheritance. Pathogenic variants were validated by Sanger sequencing using BigDye Terminator v3.1 (ABI, ThermoFisher Scientific Corporation, Waltham, MA, USA). Resulting chromatograms were analyzed using Mutation Surveyor (Softgenetics, State College, PA, USA). Tumor DNA, where available, was extracted to assess for LOH of pathogenic variants. Patient genomic DNA was also analyzed for copy number variations using digital multiplex ligation-dependent probe amplification (digitalMLPA) ([Supplementary Materials](#sup1){ref-type="supplementary-material"}, available online). Genetic testing was performed exclusively on affected patients; relatives were not included.

Selection of CRC Predisposition and DNA Repair Genes
----------------------------------------------------

In sum, 20 CRC predisposition and 44 DNA repair genes associated with cancer susceptibility were evaluated. CRC predisposition genes include *APC, AXIN2, BMPR1A, BRAF, CDH1, CHEK2, EPCAM, FLCN, GREM1, MLN1, MSH2, MSH6, MUTYH, PMS2, POLD1, POLE, PTEN, SMAD4, STK11* and *TP53.* DNA repair genes include *ATM, ATR, BAP1, BARD1, BLM, BRCA1, BRCA2, BRIP1, CDKN2A, CDK4, DDB2, ERCC2, ERCC3, ERCC4, ERCC5, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, GEN1, MITF, MRE11A, NBN, NTHL1, PALB2, RAD50, RAD51, RAD51C, RAD51D, RAD54L, RECQL4, RET, RFWD3, SLX4, UBE2T, WRN, XPA, XPC*, and *XRCC2.*

Statistical Analysis
--------------------

Patient characteristics and sequencing results were summarized as mean (SD) or median (interquartile range) for continuous variables and proportions for categorical variables. Prevalence (95% confidence interval \[CI\]) of variants were estimated as a proportion of young-onset CRC patients. χ^2^, Fisher exact test, and one-way ANOVA were used to compare clinicopathological variables among carriers and noncarriers of pathogenic variants.

Cell Treatment
--------------

Patient-derived lymphoblastoid cells (LCLs) were treated with 10 µM etoposide for 1 hour, subsequently recovered by incubation in fresh medium for 1 hour or 6 hours, and then harvested for immunoblot and immunofluorescence analyses. Vehicle control contained an equivalent volume of dimethyl sulfoxide.

Immunoblot
----------

Subcellular fractionation was performed using the nuclear/cytoplasmic separation protocol previously described ([@pky054-B22]). Fractionated proteins were electrophoresed on sodium-dodecyl-sulfate polyacrylamide gel and transferred to polyvinylidene difluoride membrane (Milipore, Sigma-Aldrich, St. Louis, MO, USA). Membranes were blocked, incubated overnight with primary antibody followed by secondary horseradish peroxidase-conjugated anti-rabbit or anti-mouse immunoglobulin (DakoCytomation, Glostrup, Denmark; P044701 and P044801, 1/10 000). Immunoreactivity was detected with enhanced chemilumescent horseradish peroxidase substrate (Advansta, Menlo Park, CA, USA) and quantified using ImageJ (NIH, MD, USA) software.

Immunofluorescence
------------------

Cells were fixed 15 minutes using 4% paraformaldehyde, permeabilized 5 minutes using 0.3% Triton-X 100, and blocked 30 minutes with 10% goat serum in phosphate-buffered saline before incubation at 37ºC for 30 minutes with primary antibodies. Slides were stained with AlexaFluor 488 or 594 conjugated secondary antibodies (ThermoFisher Scientific Corporation; A11008 and A11020, 1:1000) and mounted with Prolong Gold antifade reagent with 4′, 6-diamidino-2-phenylindole (Life Technologies, ThermoFisher Scientific Corporation). Images were acquired by confocal microscope (Zeiss LSM800). Cells containing five or more foci were scored positive for RAD51 foci formation.

Results
=======

Clinicopathological Characteristics of Patients
-----------------------------------------------

Of the 88 young CRC patients, males and females were equally represented; the majority was Chinese (73.9%). Age at diagnosis averaged 41 years, ranging from 17 to 49 years. Most patients had left-sided colorectal cancer (80.7%) and were diagnosed at late stages (AJCC stage III and IV; 84.1%). Other than young age at diagnosis, high-risk phenotypic features necessitating clinical genetic testing were absent in most patients; more than half of the patients did not have first-degree relatives with cancer and only four patients had a personal history of multiple colonic polyps ([Table 2](#pky054-T2){ref-type="table"}). Adenocarcinoma, not otherwise specified, was the most common histological subtype. Full clinicopathological data are summarized in [Table 1](#pky054-T1){ref-type="table"}. Table 1.Patient characteristicsCharacteristicsAll patients (n = 88)Patients without pathogenic variants (n = 76)Patients with pathogenic CRC predisposition gene variants (n = 6)Patients with pathogenic DNA repair gene variants (n = 6)*P*Sex Male44 (50.0)35 (46.1)4 (66.7)5 (83.3).149 Female44 (50.0)41 (53.9)2 (33.3)1 (16.7)Race Chinese65 (73.9)55 (72.4)4 (66.7)6 (100.0).017 Malay11 (12.5)11 (14.5)0 (0.0)0 (0.0) Indian4 (4.5)2 (2.6)2 (33.3)0 (0.0) Others8 (9.1)8 (10.5)0 (0.0)0 (0.0)Age of diagnosis, y Mean ± SE41.4 ± 8.041.8 ± 7.333.2 .6 ± 5.444.8 ± 1.9.019[\*](#tblfn1){ref-type="table-fn"} Range17 to 4917 to 4918 to 4936 to 49CRCs in first-degree relatives Present13 (18.6)8 (13.8)2 (33.3)3 (50.0).059 Absent57 (81.4)50 (86.2)4 (66.7)3 (50.0) Missing181800Breast cancers in first-degree relatives Present4 (5.7)4 (6.9)0 (0.0)0 (0.0).645 Absent66 (94.3)54 (93.1)6 (100.0)6 (100.0) Missing181800Ovarian cancers in first-degree relatives Present1 (1.4)1 (1.7)0 (0.0)0 (0.0).900 Absent69 (98.6)57 (98.3)6 (100.0)6 (100.0) Missing181800Any cancers in first-degree relatives Present32 (45.7)23 (39.7)4 (66.7)5 (83.3).416 Absent38 (54.3)35 (60.3)2 (33.3)1 (16.7) Missing181800Location of CRC Right sided17 (19.3)16 (21.1)0 (0.0)1 (16.7).447 Left sided71 (80.7)60 (78.9)6 (100.0)5 (83.3)Histological subtype Adenocarcinoma5 (5.7)3 (3.9)1 (16.7)1 (14.3).387 Mucinous adenocarcinoma8 (9.1)7 (9.2)0 (0.0)1 (14.3) Adenocarcinoma, NOS75 (85.2)66 (86.8)5 (83.3)4 (66.7)Tumor differentiation Well5 (5.7)4 (5.3)1 (16.7)0 (0.0).724 Moderate65 (73.9)55 (72.4)5 (83.3)5 (83.3) Poor6 (6.8)6 (7.9)0 (0.0)1 (16.7) Not specified12 (13.6)11 (14.5)00AJCC disease stage I1 (1.1)0 (0.0)1 (16.7)0 (0.0).022† II13 (14.8)11 (14.5)1 (16.7)1 (16.7) III47 (53.4)40 (52.6)3 (50.0)4 (66.7) IV27 (30.7)25 (32.9)1 (16.7)1 (16.7)MMR status (IHC) MMR-deficient0 (0.0)0 (0.0)0 (0.0)0 (0.0).272 MMR-proficient69 (100.0)60 (100.0)3 (100.0)6 (100.0) Missing191630ECOG at diagnosis 064 (73.6)53 (70.7)6 (100.0)5 (83.3).585 121 (2.4)20 (26.7)0 (0.0)1 (16.7) 22 (2.3)2 (2.7)0 (0.0)0 (0.0) Missing1100CEA at diagnosis 5 or less44 (50.0)36 (47.4)4 (66.7)4 (66.7).462 More than 544 (50.0)40 (52.6)2 (33.3)2 (33.3)[^1][^2]

Variant Pathogenicity in Colorectal Predisposition Genes
--------------------------------------------------------

Using whole-exome sequencing, we identified 316 germline variants fulfilling the MAF criteria described earlier ([Figure 1A](#pky054-F1){ref-type="fig"}), of which 12 were classified pathogenic. No copy number variation was identified in the entire cohort. Of the pathogenic variants identified from whole-exome sequencing, six occurred in known CRC predisposition genes: three truncating and one missense *APC* variants, and two missense *MUTYH* monoallelic variants ([Table 2](#pky054-T2){ref-type="table"}). All four *APC* variants were identified in four FAP patients with both gastric and colonic polyposis. Three patients developed rectal cancer without extracolonic involvement; the remaining patient subsequently developed a synchronous desmoid tumor and sigmoid colon cancer. Overall, compared to noncarriers, patients with pathogenic variants in CRC predisposition genes presented disease at an earlier age (mean age of 33 vs 42 years, *P *=* *.026) and at an earlier stage (33.4% at stage I and II vs 14.5%, *P *=* *.004) ([Table 1](#pky054-T1){ref-type="table"}). Table 2.Clinicopathological characteristics of pathogenic variantsPathogenic variantSexRaceCurrent age, yAge at CRC diagnosis, yOther personal history of cancersFamily history of cancers in first-degree relativesMMR status*APC* c.1884_1885delTTMaleIndian3429Familial adenomatous polyposis; multiple gastric and colonic polypsNot recorded[\*](#tblfn3){ref-type="table-fn"}Not recorded*APC* c.3921_3925del AAAAGFemaleIndian2318Familial adenomatous polyposis; single gastric and multiple colonic polypsMother (adenomatous polyposis coli)Not recorded*APC* c.4615delTMaleChinese3932Gardner syndrome, with synchronous desmoid tumor at 32yo; multiple gastric and colonic polypsMother (cervical cancer); siblings had negative findings on colonoscopyNot recorded*APC* c.3928A\>TMaleChinese2922Familial adenomatous polyposis; multiple gastric and colonic polypsPaternal cousin (unknown cancer); no family history of FAPProficient*MUTYH* c.857G\>AMaleChineseDeceased at 5049NoneNot recordedNot recorded*MUTYH* c.934-2A\>GFemaleChinese5349NoneSister (uterine cancer, 60yo); brother (colon cancer, 63yo)Proficient*ATM* c.477_481delATCTCMaleChinese4136NoneNoneProficient*BRCA2* c.9154C\>TMaleChinese5246NoneFather (Gastric cancer, 63yo)Proficient*NTHL1* c.793G\>AMaleChinese5648NoneMother (colon cancer, 68yo)Proficient*PALB2* c.1059delAMaleChinese4846NoneFather (lung cancer, 30yo); paternal uncle (colon cancer, 60yo); paternal aunt (breast cancer, 67yo); maternal uncle (melanoma, 40yo); maternal aunt (breast cancer)Proficient*WRN* c.499_500delAAFemaleChinese4844Krukenberg tumor, 44yoFather (colon cancer, 75yo); paternal aunt (colon cancer, 60yo); maternal aunt (uterine cancer); maternal cousin (ovarian cancer)Proficient*WRN* c.499_500delAAMaleChinese5549NoneFather (stomach cancer); brother (colon cancer)Proficient[^3]Table 3.Comparison of studies on pathogenic variants in CRC patientsMatthew et al. ([@pky054-B7])Pearlman et al. ([@pky054-B11])Saud et al. ([@pky054-B12])Stoffel et al. ([@pky054-B5])Our studyn = 1058 (%)n = 450 (%)n = 680 (%)n = 430 (%)n = 88 (%)Age of diagnosis (mean ± SD), y55.7 ± 12.642.568.8 ± 10.340.041.4 ± 0.8Study settingGastrointestinal cancer instituteGeneral oncology clinicsGeneral oncology clinicsCancer genetics clinicsGeneral oncology clinicGenetic studiesNext-generation sequencingNext-generation sequencingNext-generation sequencingNext-generation sequencingNext-generation sequencing digitalMLPAFunctional studiesNoneTumor LOHTumor LOHNoneTumor LOH; homologous recombination assay (RAD51)CRCs in first-degree relatives138 (13.0)33 (45.8)164 (25.0)111 (25.8)13 (18.6)Breast cancers in first-degree relatives138 (13.0)8 (11.1)85 (19.0)NA4 (5.7)Ovarian cancers in first-degree relatives23 (2.2)2 (2.8)19 (4.3)NA1 (1.4)Any cancers in first-degree relatives870 (82.2)53 (11.8)395 (59.0)NA33 (36.3)MMR-deficient tumors/MSI-H83 (14.5); 486 missing data48 (10.7); no missing data92 (16.0); 113 missing data41 (20.1); 226 missing data0 (0.0); 19 missing dataCRC predisposition genes tested*APC, BMPR1A, CDH1, CHEK2, EPCAM, MLH1, MSH2, MSH6, MUTYH, PMS2, PTEN, SMAD4, STK11, TP53APC, BMPR1A, CDH1, CHEK2, EPCAM, MLH1, MSH2, MSH6, MUTYH, PMS2, PTEN, SMAD4, STK11, TP53APC, BMPR1A, CHEK2, MLH1, MSH2, MSH6, MUTYH, PMS2, POLD1, POLE, PTEN, SMAD4, STK11, TP53APC, AXIN2, BMPR1A, BRAF, CDH1, CHEK2, EPCAM, KRAS, MLH1, MSH2, MSH6, MUTYH, PMS2, POLD1, POLE, PTEN, SMAD4, STK11, TP53APC, AXIN2, BMPR1A, BRAF, CDH1, CHEK2, EPCAM, FLCN, GREM1, MLN1, MSH2, MSH6, MUTYH, PMS2, POLD1, POLE, PTEN, SMAD4, STK11, TP53*DNA repair genes tested*ATM, BARD1, BRCA1, BRCA2, BRIP1, CDK4, CDKN2A, CHEK2, NBN, PALB2, RAD51C, RAD51DATM, BARD1, BRCA1, BRCA2, BRIP1, CDK4, CDKN2A, CHEK2, NBN, PALB2, RAD51C, RAD51DATM, ATR, BAP1, BARD1, BLM, BRCA1, BRCA2, BRIP1, DDB2, ERCC2, ERCC3, ERCC4, ERCC5, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, GEN1, MRE11, NBN, NTHL1, PALB2, PCNA, POLH, RAD51, RAD51C, RAD51D, RAD54L, RECQL4, SLX4, UBE2T, WRN, XPA, XPC, XRCC3AKT1, ALK, ARID1A, ATR, AURKA, BAP1, BARD1, BRCA1, BRCA2, BRIP1, CASP8, CDKN2A, CTNNB1, ERBB3, FAM123B, FAT1, FBXW7, FGFR3, GALNT12, GREM1, HNF1A, HOXB12, HRAS, IGF1, IGF2, IGF2R, MEN1, MET, MSH3, MYC, NBN, NOTCH1, PALB2, PIK3CA, PTCH1, PTPN11, RAD51, SDHB, SMAD2, SMAD3, SMAD7, SOX9, SYNE1, TERT, TET2, TGFRB2, VHLATM, ATR, BAP1, BARD1, BLM, BRCA1, BRCA2, BRIP1, CDKN2A, CDK4, DDB2, ERCC2, ERCC3, ERCC4, ERCC5, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, GEN1, MITF, MRE11A, NBN, NTHL1, PALB2, RAD50, RAD51, RAD51C, RAD51D, RAD54L, RECQL4, RET, RFWD3, SLX4, UBE2T, WRN, XPA, XPC, XRCC2*DNA usedGermline DNAGermline DNA and tumor DNAGermline DNAGermline DNAGermline DNA and tumor DNAPathogenic variants in CRC predisposition genes*MLH1* (n=13), *MSH2* (n=7), *MSH6* (n=6), *PMS2* (n=7), *MUTYH* biallelic (n=3), *APC* (n=19), *MUTYH* monoallelic (n=18), *CHEK2* (n=2)*MLH1* (n=13), *MSH2* (n=16), *MSH6* (n=2), *PMS2* (n=5), *MUTYH* biallelic (n=4), *APC* (n=10), *MUTYH* monoallelic (n=7), *SMAD4* (n=1)*MSH2* (n=1), *MSH6* (n=1), *PMS2* (n=2), *APC* (n=10), *MUTYH* monoallelic (n=11), *CHEK2* (n=4), *TP53* (n=2)*MLH1* (n=24), *MSH2* (n=25), *MSH6* (n=5), *PMS2* (n=2), *MUTYH* biallelic (n=6), *APC* (n=8), *MUTYH* monoallelic (n=1), *SMAD4* (n=2), *CHEK2* (n=1)*APC* (n=4), *MUTYH* monoallelic (n=2)Pathogenic variants in DNA repair genes*ATM* (n=10), *BARD1* (n=1), *BRCA1* (n=3), *BRCA2* (n=8), *BRIP1* (n=3), *CDKN2A* (n=1), *NBN* (n=2), *PALB2* (n=2), *TP53* (n=1)*ATM* (n=4), *BRCA1* (n=2), *BRCA2* (n=4), *CDKN2A* (n=1) and *PALB2* (n=2)*ATM* (n=5), *BAP1* (n=1), *BARD1* (n=1), *BLM* (n=3), *BRCA1* (n=1), *BRCA2* (n=4), *BRIP1* (n=2), *ERCC2* (n=2), *ERCC3* (n=1), *ERCC4* (n=1), *FANCC* (n=1), *FANCE* (n=1), *FANCL* (n=1), *GEN1* (n=2), *MRE11* (n=2), *PALB2* (n=3), *POLH* (n=1), *RECQL4* (n=2), *SLX4* (n=1), *XPA* (n=1), *XRCC3* (n=1)*BRCA1* (n=1), *TP53* (n=1)*ATM* (n=1), *BRCA2* (n=1), *NTHL1* (n=1), *PALB2* (n=1), *WRN* (n=2)Features of patients with pathogenic CRC predisposition gene variants[\*](#tblfn4){ref-type="table-fn"}Younger age†Younger ageYounger ageRight-sided colon involvement†Younger age†Right-sided colon involvement†Right-sided colon involvementFamily history of breast cancers†MSI tumors†Earlier stage of diagnosis†Earlier stage of diagnosis†Earlier stage of diagnosisMSI tumorsFamily history of CRCs†MSI tumors†MSI tumorsEarlier stage of diagnosis†Personal and family history of multiple CRCs†Personal and family history of multiple CRCs[\*](#tblfn4){ref-type="table-fn"}Features of patients with pathogenic DNA repair gene variants[\*](#tblfn4){ref-type="table-fn"}NoneNoneNoneNoneNone[^4][^5]Table 4.Pathogenicity classification using ACMG criteriaVariantPopulation dataPredictive dataFunctional dataSegregation dataDe novo dataAllelic dataReputable database\*ReferencesPathogenic/likely pathogenic *APC* c.1884_1885delPM2PVS1NANANANANA *APC* c.3921_3925delPM2PVS1PM1NANANAPP5 *APC* c.4615delTPM2PVS1NANANANANA *APC* c.3928A\>TPM2PVS1PM1NANANANA *MUTYH* c.857G\>APM2PP3PS3NANANAPP5 *MUTYH* c.934-2A\>GBS1PVS1PS3NANANAPP5 *ATM* c.477_481delATCTCPM2PVS1NANANANAPP5 *BRCA2* c.9154C\>TPM2PP3PS3NANANAPP5 *NTHL1* c.793G\>APM2PP3PM1NANANANA *PALB2* c.1059delAPM2PVS1NANANANAPP5 *WRN* c.499_500delAAPM2PVS1PM1NANANANAVUS *BRCA2* c.440A\>GPM2NANANANANANA([@pky054-B45])[^6]

![**A**) Variants identified in this study. **B**) Locations of pathogenic DNA repair variants. Red represents frameshift mutations; blue represens missense mutations. *BRCA2* c.440A\>G (p.Q147R) is a VUS included in the functional studies. CRC = colorectal cancer; VUS = variants of uncertain significance.](pky054f1){#pky054-F1}

Variant Pathogenicity in DNA Repair Genes
-----------------------------------------

The remaining half of the pathogenic variants occurred in DNA repair genes, affecting six patients. Clinically, carriers of pathogenic variants in DNA repair genes were similar to noncarriers ([Table 1](#pky054-T1){ref-type="table"}). These variants included one truncating *ATM* variant, one missense *BRCA2* variant, one missense *NTHL1* variant, one truncating *PALB2* variant, and two truncating *WRN* variants ([Table 2](#pky054-T2){ref-type="table"}). Notably, two of the six variants occurred in *BRCA2* and *PALB2*. BRCA2 and PALB2 form a protein complex essential for RAD51 nuclear localization, which is critical for the repair process ([@pky054-B31]). As both *BRCA2* and *PALB2* pathogenic variants occurred in domains key to proper RAD51 localization ([Figure 1B](#pky054-F1){ref-type="fig"}), we hypothesized that these mutations would impair RAD51 nuclear localization and foci formation. To validate our hypothesis, we performed immunoblotting and immunofluorescence assays for *BRCA2* c.9154C\>T and *PALB2* c.1059delA variants.

Functional Studies
------------------

To assess the functional impact of *BRCA2* c.9154C\>T and *PALB2* c.1059delA, we induced double-stranded DNA breaks and measured the HR efficiency by quantifying the RAD51 nuclear localization and foci formation on patient-derived LCLs. Compared to healthy controls, *BRCA2* and *PALB2* mutation carriers showed impaired RAD51 nuclear localization and foci formation ([Figures 2](#pky054-F2){ref-type="fig"} and [3](#pky054-F3){ref-type="fig"}). To further support the tumorigenesis role of these variants, we assessed for tumor LOH but did not observe LOH of *PALB2* ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}, available online). LOH data was unavailable for *BRCA2* c.9154C\>T due to insufficient tumor sample.

![**A**) Nuclear localization of RAD51 expressed as a ratio of nuclear (N) to cytoplasmic (C) RAD51 levels. Cells with *BRCA2* c.9154C\>T, *PALB2* c.1059delA, and *BRCA2* c.8945_8946delAA show impaired RAD51 nuclear localization at the first hour posttreatment, whereas those with *BRCA2* c.440A\>G displayed normal RAD51 nuclear localization. Triplicates were performed for patients with pathogenic variants. Three healthy controls were used and duplicates were done per control. *BRCA2* c.8945_8946delAA was included as a positive control. Independent *t* test was used to compare RAD51 nuclear localization between variants and healthy controls. A single asterisk (\*) refers to *P *\<* *.05, a double (\*\*) to *P *\<* *.005. **B**) Representative blot showing changes in nuclear and cytoplasmic RAD51 levels at 1 hour and 6 hours following etoposide treatment. In the healthy controls, nuclear RAD51 was higher than the cytoplasmic RAD51 following treatment. In contrast, the nuclear RAD51 remained similar to the cytoplasmic RAD51 in *BRCA2* c.9154C\>T, *PALB2* c.1059delA, and *BRCA2* c.8945_8946delAA. DMSO = dimethyl sulfoxide.](pky054f2){#pky054-F2}

![**A**) Immunofluorescence analysis of RAD51 foci formation (represented as green foci) following etoposide treatment. Compared to healthy controls, RAD51 foci formation was impaired for *BRCA2* c.9154C\>T, *PALB2* c.1059delA, and *BRCA2* c.8945_8946delAA. **B**) Percentage of cells with more than 5 RAD51 foci. Impaired RAD51 foci formation was noted for *BRCA2* c.9154C\>T, *PALB2* c.1059delA, and *BRCA2* c.8945_8946delAA at 6 hours following treatment. Triplicates were performed for patients with pathogenic variants. Duplicates were done per healthy control. *BRCA2* c.8945_8946delAA was included as a positive control. Independent *t* test was used to compare RAD51 nuclear localization between variants and healthy controls. A single asterisk (\*) refers to *P* \< .05; a double (\*\*) refers to *P* \< .005. DMSO = dimethyl sulfoxide.](pky054f3){#pky054-F3}

Among the 236 variants of uncertain significance (VUS), eight occurred in *BRCA2* and *PALB2*. Of these, we were only able to obtain LCL of *BRCA2* c.440A\>G, which occurred in a site with no known function ([Figure 1B](#pky054-F1){ref-type="fig"}). As the variant was enriched among patients (MAF \< 0.005; OR = 2.34, 95% CI = 0.49 to 11.18) and located near the PALB2-binding domain responsible for PALB2-RAD51 interaction ([Figure 1B](#pky054-F1){ref-type="fig"}), we evaluated this variant functionally but found no evidence of perturbed RAD51 foci formation or tumor LOH ([Figures 2](#pky054-F2){ref-type="fig"} and [3](#pky054-F3){ref-type="fig"}; [Supplementary Figure 1](#sup1){ref-type="supplementary-material"}, available online).

Discussion
==========

To the best of our knowledge, this was the first study of pathogenic DNA repair gene variants in Asian patients with young-onset CRCs. Similar to previous studies, we found most patients presented advanced-stage diseases in their forties ([@pky054-B2],[@pky054-B11],[@pky054-B23]). Another characteristic feature was a predilection for the distal colon and rectum, which would manifest as early symptoms of changes in bowel habit and constipation ([@pky054-B24]). Unfortunately, because of the patients' relatively young age, clinicians tended to dismiss these nonspecific symptoms, hence delaying diagnosis and treatment ([@pky054-B24]).

Exceptions to this trend were patients with high-risk phenotypic features such as personal or family history of hereditary CRC syndromes or pathogenic variants in CRC predisposition genes. Studies on young-onset CRCs, including ours, observed that these patients were often diagnosed at a younger age and earlier disease stages compared with their peers who lack those features ([@pky054-B5],[@pky054-B7],[@pky054-B11],[@pky054-B12]). This pattern of diagnosis might be related to the close surveillance and prompt treatment received by at-risk patients, which often translated to improved survival outcomes ([@pky054-B25]). These benefits could be extended to more patients, given that young-onset CRCs had a heritable component beyond CRC predisposition genes.

Previously, pathogenic variants identified among CRC patients predominantly involved CRC predisposition genes, partly because of use of limited gene panels ([@pky054-B5],[@pky054-B10],[@pky054-B11]). Broader use of pan-cancer panels resulted in increasing discovery of pathogenic variants in DNA repair genes and an enrichment of pathogenic *PALB2* variants was observed in a study on CRC patients ([@pky054-B5],[@pky054-B7],[@pky054-B11],[@pky054-B12]). It is conceivable that HR deficiency contributed to CRC tumorigenesis, given the indispensable role of HR in repair of highly damaging double-stranded DNA breaks ([@pky054-B26]).

In accordance with the Knudson two-hit hypothesis, deficient repair process and eventual tumorigenesis resulted from the inactivation of a wild-type allele in an individual with a germline pathogenic variant ([@pky054-B27]). Although tumor LOH has not been reported in patients with *PALB2* and *BRCA2* pathogenic variants, these variants could still be relevant in CRC tumorigenesis. Here, we demonstrated that *BRCA2* and *PALB2* monoallelic pathogenic variants were associated with impaired RAD51 foci formation. Likewise, previous studies established haploinsufficiency for both *BRCA2* and *PALB2* where a monoallelic pathogenic variant sufficed to directly impair function or promote the inactivation of the wild-type allele ([@pky054-B28],[@pky054-B29]). In addition, tumor LOH was absent in most *PALB2* germline mutation carriers and most *PALB2* heterozygous cancers displayed high HR deficiency scores ([@pky054-B12],[@pky054-B30]). An impaired HR might predispose the patient to worsening genomic instability and eventual tumorigenesis ([@pky054-B26]). Clinically, patients with pathogenic variants in DNA repair genes did not share any characteristic phenotype suggestive of a distinct CRC subset, unlike those with pathogenic variants in the CRC predisposition genes who tended to be younger with more right-sided colon involvement and earlier disease stages ([@pky054-B5],[@pky054-B7],[@pky054-B11],[@pky054-B12]). To ascertain whether germline pathogenic variants in HR genes were truly drivers of CRCs and whether these CRCs shared a distinct tumor phenotype, more studies on tumor LOH and mutational signatures in various HR-deficient CRCs will be needed.

Besides HR, there were other prominent DNA repair pathways such as nonhomologous end joining and base excision repair ([@pky054-B29],[@pky054-B31],[@pky054-B32]). Nonhomologus end joinging was the alternative repair process for double-stranded DNA breaks under regulation by checkpoint kinases such as *ATM* ([@pky054-B32]). Germline variants of *ATM* were associated with autosomal recessive ataxia telangiectasia and autosomal dominant cancers, namely breast cancer. More recently, pathogenic variants in *ATM* were also found to be enriched in CRC patients ([@pky054-B7],[@pky054-B11],[@pky054-B12]). However, the precise CRC risks for *ATM* pathogenic variants were unclear and *ATM* was not considered a CRC predisposition gene by the National Comprehensive Cancer Network guidelines ([@pky054-B12],[@pky054-B33]).

Apart from *ATM*, we identified monoallelic variants in *NTHL1* and *WRN.* The *NTHL1* gene was involved in base excision repair, and was recently validated as an autosomal recessive CRC susceptibility gene after *NTHL1* biallelic variants were found to cause CRCs ([@pky054-B36]). A homozygous nonsense variant in *NTHL1* (p.Gln90\*) was detected among seven CRC patients from three unrelated families whereas compound heterozygous *NTHL1* variants were found in a patient with multiple primary tumors, including CRC ([@pky054-B38]). For *WRN*, which encoded for a helicase with exonuclease function, preliminary studies hinted at the possibility of WRN-BRCA1 interaction in HR pathway ([@pky054-B39]). Pathogenic variants in *WRN* were predominantly truncating and *WRN* somatic hypermethylation was also observed in various tumors, including colon tumors ([@pky054-B40]). However, the increased risk of neoplasia was only seen in biallelic *WRN* mutations ([@pky054-B41]). Similar to *NTHL*, the unclear role of *WRN* monoallelic variants in young-onset CRCs will require further evaluation.

The cumulative risk of young-onset CRC associated with *MUTYH* monoallelic variants was modest and statistically insignificant (0.8%, 95% CI = 0.5% to 1.3%), unlike those of biallelic *MUTYH* variants (24.8%, 95% CI = 7.7% to 57.1%) ([@pky054-B42]). Moreover, the frequency of *MUTYH* monoallelic variants in CRC patients (1.6% to 2.2%) was similar to that of controls (1.7%) ([@pky054-B7],[@pky054-B11],[@pky054-B12],[@pky054-B43]). Currently, CRC screening guidelines do not require carriers of *MUTYH* monoallelic variants to undergo more intensive screening than the general population ([@pky054-B44]).

In addition to identifying pathogenic variants, we functionally evaluated a VUS in *BRCA2* (c.440A\>G)*.* This variant was previously reported in a Chinese family with multiple breast cancers where it was found in all three sisters with breast cancers and absent in the father and another unaffected sister ([@pky054-B45]). However, we did not observe any functional evidence for pathogenicity consistent with the low in silico prediction score for pathogenicity (REVEL score = 0.338). Hence we concluded that this variant was unlikely to be pathogenic.

However, our study has several limitations. We had a small sample size of 88 patients. Our study was thus underpowered to perform statistical inference of the odds ratio, which was required as part of the ACMG curation criteria ([@pky054-B20]). Nonetheless, we identified similar clinical and genetic features as the larger studies. In addition, our cohort had similar characteristics of young-onset CRCs as the earlier studies. Another limitation was that we were unable to perform tumor LOH analysis for the *MUTYH* pathogenic variants, which would have been useful in confirming their pathogenicity status.

To reliably interpret germline variants, both genetic and functional evidence are required. Currently, there is a lack of functional validation of pathogenic variants in the DNA repair genes. Most were limited to tumor LOH studies. Although presence of biallelic inactivation offered evidence for the variant as a driver mutation, monoallelic variants could still have an impact on tumorigenesis. Direct assessment of protein function would be essential to determine the pathogenicity of a variant in question, especially for genes such as *BRCA2* and *PALB2*, which exhibited haploinsufficiency and did not require LOH to exert deleterious functional effects ([@pky054-B31],[@pky054-B32]). Complementing tumor LOH studies, our patient-based RAD51 assays could directly evaluate the function of the variant protein.

A substantial portion of patients with young-onset CRC harbored germline pathogenic variants. Excluding those with hereditary CRC syndromes, most patients with pathogenic variants did not have high-risk phenotypic features. Hence, germline genetic testing should preferably be performed for all young-onset CRC patients. Screening of germline variants in HR genes such as *BRCA2* and *PALB2* might improve the yield of germline genetic testing. These genes contributed a considerable portion of the pathogenic variants identified among young-onset CRCs and many had established risk management guidelines ([@pky054-B46]). Furthermore, pathogenic variants in these genes do exert functional consequences and are potentially tumorigenic. Although these genes have yet to be acknowledged as CRC predisposition genes, the evidence is growing. Larger population studies and genome-wide association studies will provide the much-needed conclusion on their relevance in CRC tumorigenesis.
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[^1]: Post hoc analysis showed statistically significant differences when comparing patients with pathogenic CRC predisposition gene variants against those without any pathogenic variants (*P* = .026) and those with pathogenic DNA repair gene variants (*P* = .027). AJCC = American Joint Committee on Cancer; CEA = carcinoembryonic antigen test; CRC = colorectal cancer; ECOG = Eastern Cooperative Oncology Group Performance Status; IHC = immunohistochemistry; MMR = mismatch repair; NOS = not otherwise specified.

[^2]: Statistically significant difference was observed between patients with pathogenic CRC predisposition gene variants and those without any pathogenic variants (*P* = .004).

[^3]: Not recorded in the patient's electronic medical records. CRC = colorectal cancer.

[^4]: Compared to noncarriers of germline pathogenic variants. CRC= colorectal cancer; digitalMLPA = digital multiplex ligation-dependent probe amplification; MMR= mismatch repair; MSI-H = microsatellite instability-high.

[^5]: Statistical significance (*P* \< .05) was observed.

[^6]: \*Variants were assessed for pathogenicity using ClinVar archives, Mastermind search engine by Genomenon, and genetic databases such as the Leiden Open Variation Database (LOVD), BRCA Exchange, InSiGHT, and ARUP MEN2 database. VUS = variants of uncertain significance.
